Bavarian Nordic – Transactions in Connection with Share Buy-Back Program and Termination of Share Buy-Back Program
21 Maggio 2024 - 11:25PM
Bavarian Nordic – Transactions in Connection with Share Buy-Back
Program and Termination of Share Buy-Back Program
COPENHAGEN, Denmark, May 21,
2024 – Bavarian Nordic A/S (OMX: BAVA) announces that the
share buy-back program, which was announced and initiated on May 8,
2024, has now been terminated, as the intended number of shares
under the program has been repurchased. The program was executed in
accordance with the provisions of Regulation (EU) No. 596/2014 of
the European Parliament and of the Council of 16 April 2014 on
market abuse and supplementing Regulation (EU) 2016/1052 of 8 March
2016, which together constitute the Safe Harbour Regulation. The
purpose of the program was to meet the Company’s obligations
arising from the share-based incentive program for the Board of
Directors and Executive Management.
Under the program Bavarian Nordic A/S has bought
back 162,288 shares, cf. the table below:
|
Transaction date |
Number of shares |
Average purchase price, DKK |
Transaction Value, DKK |
|
May 8, 2024 |
25,000 |
158.74 |
3,968,500 |
|
May 13, 2024 |
25,000 |
163.93 |
4,098,250 |
|
May 14, 2024 |
25,000 |
167.74 |
4,193,500 |
|
May 15, 2024 |
35,000 |
169.76 |
5,941,600 |
|
May 16, 2024 |
15,000 |
173.86 |
2,607,900 |
|
May 17, 2024 |
13,000 |
179,57 |
2,334,410 |
|
May 21, 2024 |
24,288 |
175.77 |
4,269,102 |
|
Accumulated under the program |
162,288 |
168.92 |
27,413,262 |
The details for each transaction made under the
share repurchase program have been attached to this
announcement.
With the transactions stated above, Bavarian
Nordic A/S owns a total of 288,222 own shares, corresponding to
0.37%% of the share capital. The total amount of shares in the
company is 78,097,834 including treasury shares.
About Bavarian NordicBavarian
Nordic is a fully integrated vaccine company with a mission to
protect and save lives through innovative vaccines. We are a global
leader in smallpox and mpox vaccines, supplied to governments to
enhance public health preparedness and have a strong portfolio of
vaccines for travelers and endemic diseases. For more information
visit www.bavarian-nordic.com.
Forward-looking statements This
announcement includes forward-looking statements that involve
risks, uncertainties and other factors, many of which are outside
of our control, that could cause actual results to differ
materially from the results discussed in the forward-looking
statements. Forward-looking statements include statements
concerning our plans, objectives, goals, future events, performance
and/or other information that is not historical information. All
such forward-looking statements are expressly qualified by these
cautionary statements and any other cautionary statements which may
accompany the forward-looking statements. We undertake no
obligation to publicly update or revise forward-looking statements
to reflect subsequent events or circumstances after the date made,
except as required by law.
ContactsEurope: Rolf Sass
Sørensen, Vice President Investor Relations,
rss@bavarian-nordic.com, Tel: +45 61 77 47 44 US: Graham Morrell,
graham@paddockcircle.com, Tel: +1 781 686 9600
Company Announcement no. 15 / 2024
Grafico Azioni Bavarian Nordic AS (TG:BV3)
Storico
Da Ott 2024 a Nov 2024
Grafico Azioni Bavarian Nordic AS (TG:BV3)
Storico
Da Nov 2023 a Nov 2024
